Endogenous p53 inhibitor TIRR dissociates systemic metabolic health from oncogenic activity - Tsaousidou, Eva; Chrzanowski, Jędrzej; Drané, Pascal; Lee, Grace Y.; Bahour, Nadine; Wang, Zeqiu Branden; Deng, Shijun; Cao, Zhe; Huang, Kaimeng; He, Yizhou; Kaminski, Mateusz; Michalek, Dominika; et al. (Cell reports (Cambridge), 2024)
Keywords: Adipose Tissue - metabolism; Animals; cancer metabolism; cancer mouse model of p53 activation; cancer protection; Carcinogenesis - metabolism; Carcinogenesis - pathology; CP: Cancer; CP: Metabolism; Glucose - metabolism; Humans; in vivo physiology in cancer; Insulin Resistance; Male; mevalonate pathway suppression; Mice; Mice, Inbred C57BL; Mice, Knockout; obesity and cancer; overweight and cancer; p53 activation; p53 derepression; p53 inhibitor; RNA-Binding Proteins - metabolism; Tumor Suppressor Protein p53 - metabolism; type 2 diabetes and cancer; obesity and cancer; cancer protection; type 2 diabetes and cancer; p53 derepression; p53 activation; CP: Metabolism; overweight and cancer; mevalonate pathway suppression; cancer mouse model of p53 activation; p53 inhibitor; in vivo physiology in cancer; cancer metabolism; CP: Cancer